17:31 , Sep 26, 2018 |  BC Innovations  |  Distillery Techniques

Assay and screens; other

TECHNOLOGY: Cell-free assays; computational models A computational model based on mutations in plasma cell-free DNA (cfDNA) could help predict the time to progression in mCRC patients treated with anti-EGFR therapies. Construction of the model involves three...
15:18 , Sep 14, 2018 |  BC Week In Review  |  Company News

GNS, Amgen to use AI to explore patient response to mCRC drug Vectibix

GNS Healthcare Inc. (Cambridge, Mass), Amgen Inc. (NASDAQ:AMGN) and the Alliance for Clinical Trials in Oncology (Boston, Mass.) partnered to use artificial intelligence to identify factors that drive and predict patient responses to Amgen’s metastatic...
15:32 , May 25, 2018 |  BC Week In Review  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
23:26 , May 18, 2018 |  BC Extra  |  Clinical News

Abeona reports updated data for MPS IIIA gene therapy

Abeona Therapeutics Inc. (NASDAQ:ABEO) said ABO-102 led to significant dose- and time-dependent reductions in CSF and urine heparan sulfate levels through 18 months in a Phase I/II trial to treat mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo...
14:11 , May 18, 2018 |  BC Week In Review  |  Clinical News

Endocyte's radioligand therapy reduces PSA in CRPC patients

Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels in a Phase II trial to treat metastatic castration-resistant prostate cancer (CRPC). The data were released in an abstract...
21:07 , May 16, 2018 |  BC Extra  |  Clinical News

Endocyte's radioligand therapy reduces PSA in CRPC patients

Newly released data showed that 177Lu-PSMA-617 from Endocyte Inc. (NASDAQ:ECYT) reduced prostate-specific antigen (PSA; KLK3) levels in a Phase II trial to treat metastatic castration-resistant prostate cancer. The data were released in an abstract ahead...
21:06 , Apr 6, 2018 |  BioCentury  |  Finance

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
19:32 , Oct 6, 2017 |  BC Week In Review  |  Company News

ABX grants Endocyte exclusive, worldwide rights to PSMA-targeting ligand

ABX GmbH (Radeberg, Germany) granted Endocyte Inc. (NASDAQ:ECYT) exclusive, worldwide rights to develop and commercialize prostate-specific membrane antigen (PSMA; FOLH1; GCPII)-targeting ligand PSMA-617. ABX received $12 million up front and is eligible for up to $160...
23:20 , Oct 2, 2017 |  BC Extra  |  Company News

Endocyte soars on deal for ABX's CRPC candidate

Endocyte Inc. (NASDAQ:ECYT) jumped $2.22 (157%) to $3.63 on Monday after ABX GmbH (Radeberg, Germany) granted the biotech exclusive, worldwide rights to develop and commercialize prostate-specific membrane antigen (PSMA; FOLH1; GCPII)-targeting ligand PSMA-617. ABX received $12...
11:38 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

ABO-102: Interim Ph I/II data

Interim data from 3 patients with MPS IIIA in an open-label, U.S. Phase I/II trial showed that a single IV injection of 5x1012 vg/kg ABO-102 was well tolerated with no treatment-related serious adverse events through...